Citizens raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $745 from $527 and keeps an Outperform rating on the shares. Rezdiffra’s extended intellectual property coverage and multiple shots on goal with combination candidates lends more confidence in MASH revenues extending into the 2040s, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen
- Madrigal: Expanding MASH Franchise and Combination Therapy Strategy Drive Raised Price Target and Reaffirmed Buy Rating
- Madrigal Pharmaceuticals expands MASH pipeline with global license agreement
- Morning Movers: OneStream surges following report of Hg takeover talks
- Wolfe downgrades Madrigal Pharmaceuticals to Peer Perform on valuation